Lithium Carbonate ER

MARCH 01, 2004

Roxane Laboratories Inc (Columbus, Ohio) recently announced the approval of Lithium Carbonate Extended Release Tablets USP, 450 mg. This product is ABrated to GlaxoSmithKline?s Eskalith CR (lithium carbonate) 450 mg. Lithium Carbonate Extended Release Tablets are indicated for the treatment of manic episodes of manic?depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic?depressive patients with a history of mania. The tablets may produce a normalization of symptomatology within 1 to 3 weeks. For more information, visit www.roxane.com.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.